Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
In the latest session, Protagonist Therapeutics Inc (NASDAQ: PTGX) closed at $36.54 down -3.69% from its previous closing price of $37.94. In other words, the price has decreased by -$3.69 from its previous closing price. On the day, 0.67 million shares were traded. PTGX stock price reached its highest trading level at $37.68 during the session, while it also had its lowest trading level at $35.03.
Ratios:
For a deeper understanding of Protagonist Therapeutics Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.65 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 9.50. For the most recent quarter (mrq), Quick Ratio is recorded 10.70 and its Current Ratio is at 10.70. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on December 06, 2024, initiated with a Neutral rating and assigned the stock a target price of $47.
On December 06, 2024, BMO Capital Markets started tracking the stock assigning a Outperform rating and target price of $62.
On November 05, 2024, Wedbush started tracking the stock assigning a Outperform rating and target price of $58.Wedbush initiated its Outperform rating on November 05, 2024, with a $58 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 27 ’24 when MOLINA ARTURO MD sold 26,000 shares for $44.70 per share. The transaction valued at 1,162,280 led to the insider holds 46,444 shares of the business.
MOLINA ARTURO MD sold 5,529 shares of PTGX for $252,122 on Nov 26 ’24. The Chief Medical Officer now owns 46,444 shares after completing the transaction at $45.60 per share. On Nov 25 ’24, another insider, Gupta Suneel, who serves as the Chief Development Officer of the company, sold 103,437 shares for $46.04 each. As a result, the insider received 4,762,239 and left with 256,174 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PTGX now has a Market Capitalization of 2177710848 and an Enterprise Value of 1719890560. As of this moment, Protagonist’s Price-to-Earnings (P/E) ratio for their current fiscal year is 13.71. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.73 while its Price-to-Book (P/B) ratio in mrq is 4.09. Its current Enterprise Value per Revenue stands at 5.312 whereas that against EBITDA is 11.461.
Stock Price History:
The Beta on a monthly basis for PTGX is 2.22, which has changed by 0.53169155 over the last 52 weeks, in comparison to a change of 0.22677135 over the same period for the S&P500. Over the past 52 weeks, PTGX has reached a high of $48.89, while it has fallen to a 52-week low of $23.17. The 50-Day Moving Average of the stock is -11.49%, while the 200-Day Moving Average is calculated to be -3.47%.
Shares Statistics:
For the past three months, PTGX has traded an average of 669.64K shares per day and 599670 over the past ten days. A total of 59.52M shares are outstanding, with a floating share count of 56.09M. Insiders hold about 5.89% of the company’s shares, while institutions hold 100.95% stake in the company. Shares short for PTGX as of 1735603200 were 3798682 with a Short Ratio of 5.67, compared to 1732838400 on 3399522. Therefore, it implies a Short% of Shares Outstanding of 3798682 and a Short% of Float of 6.460000000000001.
